OR WAIT null SECS
March 17, 2023
Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.
Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.
March 14, 2023
Webinar Date/Time: Tue, Apr 4, 2023 11:00 AM EDT
March 08, 2023
Webinar Date/Time: Thu, Mar 30, 2023 11:00 AM EDT
February 17, 2023
In this paper, the authors lay out some commonly accepted HCP analytical methods, the challenges of HCP assay, and provide recommendations on what can easily be accomplished in-house and when it may be better to outsource.
February 15, 2023
Shifting toward more technological solutions and ensuring a greater understanding of the workforce’s needs will give both CROs and sponsors a market advantage.
February 03, 2023
Efforts to optimize the delivery of sensitive biotherapeutics continue to evolve.
January 03, 2023
Bio/pharma has evolved and adapted to a variety of challenges in 2022, but what might be on the cards for the industry in 2023?
January 02, 2023
TreeFrog Therapeutics is leaping ahead in cell therapies through resources such as new technologies and investor partnerships.
The latest report from Clarivate has been published, highlighting 15 potential blockbusters to watch out for in 2023, the majority of which are personalized medicines.